Trial Profile
Functional Evaluation Of The autonomic nervous system in the context of the first intake of 0.5 mg of fingolimod (Gilenya) in patients with relapsing-leveling multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Autonomic-nervous-system-disorders; Multiple sclerosis
- Focus Pharmacodynamics
- 28 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2015 Planned End Date changed from 1 Aug 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.
- 02 Feb 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.